Targeting osteoclasts is clinically beneficial for prostate cancer patients, since it has been shown that the morbidity related to skeletal events is reduced when prostate cancer patients are treated with denosumab, an inhibitor for RANKL [22,23] or zoledronic acid, an inhibitor of osteoclastic activity [24]. This evidence concerns the gene TNFSF11 and prostate cancer.